3 transcripts
HBIO
Earnings call transcript
NASDAQ
2024 Q1
7 May 24
represents nearly 85% of total revenue, in which we target to deliver better-than-market growth.
We invest to continue our leadership position
HBIO
Earnings call transcript
NASDAQ
2023 Q4
7 Mar 24
the world in leading clinical laboratories.
Finally, we're focusing on commercializing our leadership position in advanced cellular applications. We
HBIO
Earnings call transcript
NASDAQ
2023 Q2
8 Aug 23
to highlight our new mesh array organoid MEA platform. Building on our relationship -- our leadership position in single-well, high-density, multi
- Prev
- 1
- Next